Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

Oncomine Myeloid Assay GX

Laboratory Developed Test
Related tests:


The Ion Torrent Oncomine Myeloid Assay GX is a comprehensive targeted next-generation sequencing (NGS) assay. The Oncomine Myeloid Assay GX is the first in a series of clinical research assays available from the new suite of hematology-oncology solutions. The new panel enables simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in a single day. It also provides researchers the ability to profile 40 DNA targets and 29 fusion driver genes, enabling detection of more than 600 fusion isotypes to identify biomarkers associated with myeloproliferative neoplasm (MPN), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The Oncomine Myeloid Assay GX maximizes detection of relevant biomarkers, including TP53, CEBPA, NPM1, RUNX1, PML-RARA, IDH1, IDH2 and FLT3-ITD, a common driver mutation that is associated with poor prognosis in AML.
Acute Myelogenous Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
CEBPA (CCAAT Enhancer Binding Protein Alpha), FLT3 (Fms-related tyrosine kinase 3), IDH1 (Isocitrate dehydrogenase (NADP(+)) 1), IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), NPM1 (Nucleophosmin 1), RUNX1 (RUNX Family Transcription Factor 1)
See More ...
Next-Generation Sequencing (NGS)